Clinical Trial

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

Study acronym: VALUE-CHECK
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a prospective, open label, multi-centre phase 2 trial which assesses the efficacy and safety of standard dosing compared to extended dosing interval of nivolumab, atezolizumab or pembrolizumab in advanced/unresectable gastric/gastroesophageal junction/oesphageal adenocarcinomas with PDL1 CPS ≥5%, hepatocellular carcinoma andnon-small cell lung cancer with PDL1 TPS≥50% with no prior treatment. The investigators hypothesize that nivolumab, pembrolizumab and atezolizumab can be used efficiently at extended dosing intervals, compared to their approved labels with comparable clinical outcome.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-15; most recent amendment 2025-01-08.
Status change: Not Yet Recruiting → Recruiting 2025-01-08
Trial Details
NCT Number NCT06422403
Lead Sponsor National University Hospital, Singapore
Conditions Carcinoma, Hepatocellular, Gastric Adenocarcinoma, GastroEsophageal Cancer, Oesophageal Cancer, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Enrollment 360 participants
Start Date 2024-11-25
Primary Completion 2029-03-30 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-10